[go: up one dir, main page]

MA28495B1 - Derives d'oxadiazolone agonistes de ppar-delta - Google Patents

Derives d'oxadiazolone agonistes de ppar-delta

Info

Publication number
MA28495B1
MA28495B1 MA29354A MA29354A MA28495B1 MA 28495 B1 MA28495 B1 MA 28495B1 MA 29354 A MA29354 A MA 29354A MA 29354 A MA29354 A MA 29354A MA 28495 B1 MA28495 B1 MA 28495B1
Authority
MA
Morocco
Prior art keywords
ppar
agonist
delta
oxadiazolone derivatives
oxadiazolone
Prior art date
Application number
MA29354A
Other languages
English (en)
Inventor
Stefanie Keil
Wolfgang Wendler
Maike Glien
Jochen Goerlitzer
Karen Chandross
Daniel G Mcgarry
Jean Merrill
Patrick Bernardelli
Baptiste Ronan
Corinne Terrier
Original Assignee
Sanofi Aventis Deutschland
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi Aventis Deutschland filed Critical Sanofi Aventis Deutschland
Publication of MA28495B1 publication Critical patent/MA28495B1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Diabetes (AREA)
  • Neurosurgery (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
MA29354A 2004-04-01 2006-09-29 Derives d'oxadiazolone agonistes de ppar-delta MA28495B1 (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP04007879A EP1586573B1 (fr) 2004-04-01 2004-04-01 Oxadiazolones, procédé pour leur préparation, usage comme agents pharmaceutiques

Publications (1)

Publication Number Publication Date
MA28495B1 true MA28495B1 (fr) 2007-03-01

Family

ID=34924545

Family Applications (1)

Application Number Title Priority Date Filing Date
MA29354A MA28495B1 (fr) 2004-04-01 2006-09-29 Derives d'oxadiazolone agonistes de ppar-delta

Country Status (37)

Country Link
US (3) US20070179191A1 (fr)
EP (3) EP1586573B1 (fr)
JP (1) JP2007530612A (fr)
KR (1) KR20060135857A (fr)
CN (1) CN100582104C (fr)
AR (1) AR050576A1 (fr)
AT (1) ATE435225T1 (fr)
AU (1) AU2005231916A1 (fr)
BR (1) BRPI0509517A (fr)
CA (1) CA2561627A1 (fr)
CR (1) CR8572A (fr)
CY (1) CY1109370T1 (fr)
DE (2) DE602004004631D1 (fr)
DK (1) DK1740583T3 (fr)
DO (1) DOP2005000051A (fr)
EC (1) ECSP066892A (fr)
ES (1) ES2329484T3 (fr)
GT (1) GT200500028A (fr)
HR (1) HRP20090493T1 (fr)
IL (1) IL178056A0 (fr)
MA (1) MA28495B1 (fr)
MY (1) MY142431A (fr)
NO (1) NO20064981L (fr)
PA (1) PA8628701A1 (fr)
PE (1) PE20060323A1 (fr)
PL (1) PL1740583T3 (fr)
PT (1) PT1740583E (fr)
RS (1) RS51186B (fr)
RU (1) RU2374243C2 (fr)
SI (1) SI1740583T1 (fr)
SV (1) SV2006002071A (fr)
TN (1) TNSN06317A1 (fr)
TW (1) TW200602342A (fr)
UA (1) UA84203C2 (fr)
UY (1) UY28837A1 (fr)
WO (1) WO2005097786A1 (fr)
ZA (1) ZA200606870B (fr)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20060017929A (ko) * 2004-08-04 2006-02-28 동화약품공업주식회사 티아졸 유도체가 치환된 신규한 벤즈아미딘 유도체, 그의제조방법 및 이를 유효성분으로 하는 약학 조성물
BRPI0616477A2 (pt) 2005-09-29 2011-06-21 Sanofi Aventis derivados de 2-amintiazóis e 2-amino-oxazóis, processos para a sua preparação e seus usos
WO2007039177A2 (fr) 2005-09-29 2007-04-12 Sanofi-Aventis Derives de phenyl-1,2,4-oxadiazolone : procedes de preparation et utilisation comme produits pharmaceutiques
CN101273036A (zh) 2005-09-29 2008-09-24 塞诺菲-安万特股份有限公司 具有苯基的苯基-[1,2,4]-噁二唑-5-酮衍生物、它们的制备方法和它们作为药物的用途
KR20090066289A (ko) 2006-09-08 2009-06-23 로드아일랜드하스피틀 알코올 유발성 뇌 질환의 치료, 예방 및 역행
AU2007292874B2 (en) 2006-09-08 2013-11-21 Rhode Island Hospital Treatment, prevention, and reversal of alcohol-induced liver disease
EP1932843A1 (fr) * 2006-12-14 2008-06-18 sanofi-aventis Dérivés de sulfonyl-phenyl-2H(1,2,4) oxadiazole-5-one, procédés de préparation de ceux-ci et leur usage sous forme de médicaments
AU2009256982A1 (en) 2008-06-09 2009-12-17 Sanofi-Aventis Annelated N-heterocyclic sulfonamides with oxadiazolone headgroup, processes for their preparation and their use as pharmaceuticals
EP2288607B1 (fr) 2008-06-09 2014-09-24 Sanofi Sulfonamides comprenant un hétérocycle et un groupe de tête oxadiazolone, procédés pour les préparer et leur utilisation comme produits pharmaceutiques
WO2009149819A1 (fr) * 2008-06-09 2009-12-17 Sanofi-Aventis Pyrrolidine sulfonamides annelés avec groupement de tête oxadiazolone, procédés pour leur préparation et leur utilisation comme médicaments
EP2349285B1 (fr) 2008-10-10 2016-03-23 Dara Biosciences, Inc. Nanoemulsion comprenant des dérivés de Spicamycin pour utilisation dans le traitement de la douleur
EP3135672B9 (fr) * 2008-10-10 2020-05-20 VM Discovery, Inc. Compositions et méthodes pour traiter les troubles liés à la consommation d'alcool, la douleur et d' autres maladies
ES2439801T3 (es) * 2009-08-05 2014-01-24 Daiichi Sankyo Company, Limited Derivado de sulfona
EP2463279B1 (fr) * 2009-08-05 2014-02-12 Daiichi Sankyo Company, Limited Composés de 4-(1,2,4-dioxazol-3-yl)benzamide pour le traitement du diabète et de l'obésité
WO2015061481A1 (fr) 2013-10-23 2015-04-30 Dara Biosciences, Inc. Méthodes de traitement de tumeurs liquides à l'aide de compositions comprenant des dérivés de spicamycine
US20220387393A1 (en) * 2019-11-06 2022-12-08 Board Of Regents, The University Of Texas System Methods for the treatment of dysmyelinating/demyelinating diseases

Family Cites Families (58)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5256680A (en) 1988-11-29 1993-10-26 Warner-Lambert Company 3,5-di-tertiary-butyl-4-hydroxyphenyl-1,3,4-thiadiazoles, and oxadiazoles and 3,5-di-tertiary-butyl-4-hydroxy-phenyl-1,2,4-thiadazoles, oxadiazoles and triazoles as antiinflammatory agents
FR2663336B1 (fr) 1990-06-18 1992-09-04 Adir Nouveaux derives peptidiques, leur procede de preparation et les compositions pharmaceutiques qui les contiennent.
TW222626B (fr) * 1991-07-22 1994-04-21 Pfizer
IL108634A0 (en) 1993-02-15 1994-05-30 Wellcome Found Hypolipidaemic heterocyclic compounds, their prepatation and pharmaceutical compositions containing them
ZA941003B (en) 1993-02-15 1995-08-14 Wellcome Found Hypolipidaemic compounds
US5641796A (en) 1994-11-01 1997-06-24 Eli Lilly And Company Oral hypoglycemic agents
JP3144624B2 (ja) 1995-06-02 2001-03-12 杏林製薬株式会社 Ｎ−ベンジルジオキソチアゾリジルベンズアミド誘導体及びその製造法
CA2241567A1 (fr) 1996-01-17 1997-07-24 Novo Nordisk A/S Derives de 1,2,4-thiadiazine fusionnee et de 1,4-thiazine fusionnee, leur preparation et utilisation
UA72181C2 (uk) 1996-08-30 2005-02-15 Ново Нордіск А/С Похідна глюкагоноподібного пептиду-1 (варіанти), фармацевтична композиція та спосіб одержання лікувального засобу (варіанти), спосіб лікування діабету (варіанти) і ожиріння
TW492957B (en) 1996-11-07 2002-07-01 Novartis Ag N-substituted 2-cyanopyrrolidnes
RU2200161C2 (ru) 1996-12-31 2003-03-10 Др. Редди'З Рисерч Фаундейшн Новые производные азолидиндиона, способ их получения (варианты), фармацевтические композиции на их основе, способ предупреждения или лечения, способ снижения глюкозы и промежуточное соединение
DE19726167B4 (de) 1997-06-20 2008-01-24 Sanofi-Aventis Deutschland Gmbh Insulin, Verfahren zu seiner Herstellung und es enthaltende pharmazeutische Zubereitung
IL133604A0 (en) 1997-07-16 2001-04-30 Novo Nordisk As Fused 1, 2, 4-thiadiazine derivatives, their preparation and use
CO4970713A1 (es) 1997-09-19 2000-11-07 Sanofi Synthelabo Derivados de carboxamidotiazoles, su preparacion, composiciones farmaceuticas que los contienen
DE19823831A1 (de) 1998-05-28 1999-12-02 Probiodrug Ges Fuer Arzneim Neue pharmazeutische Verwendung von Isoleucyl Thiazolidid und seinen Salzen
MA26634A1 (fr) 1998-06-04 2004-12-20 Astra Ab Nouveaux derives de l'acide 3-aryl propionique et analogues
SE9801992D0 (sv) 1998-06-04 1998-06-04 Astra Ab New 3-aryl-2-hydroxypropionic acid derivative I
US6221897B1 (en) 1998-06-10 2001-04-24 Aventis Pharma Deutschland Gmbh Benzothiepine 1,1-dioxide derivatives, a process for their preparation, pharmaceuticals comprising these compounds, and their use
DE19828113A1 (de) 1998-06-24 2000-01-05 Probiodrug Ges Fuer Arzneim Prodrugs von Inhibitoren der Dipeptidyl Peptidase IV
DE19828114A1 (de) 1998-06-24 2000-01-27 Probiodrug Ges Fuer Arzneim Produgs instabiler Inhibitoren der Dipeptidyl Peptidase IV
DE19845405C2 (de) 1998-10-02 2000-07-13 Aventis Pharma Gmbh Arylsubstituierte Propanolaminderivate und deren Verwendung
GB9900416D0 (en) 1999-01-08 1999-02-24 Alizyme Therapeutics Ltd Inhibitors
DE19916108C1 (de) 1999-04-09 2001-01-11 Aventis Pharma Gmbh Mit Zuckerresten substituierte 1,4-Benzothiazepin-1,1-dioxidderivate, Verfahren zu deren Herstellung und deren Verwendung
WO2000063208A1 (fr) 1999-04-16 2000-10-26 Novo Nordisk A/S Imidazoles substitues, leur preparation et utilisation
DK1177187T3 (da) 1999-04-28 2007-10-15 Sanofi Aventis Deutschland Diarylsyrederivater som PPAR-receptorligander
DE60027420T2 (de) 1999-04-28 2006-11-16 Aventis Pharma Deutschland Gmbh Tri-aryl-säurederivate als ppar rezeptor liganden
AU4808300A (en) 1999-04-30 2000-11-17 Neurogen Corporation 9h-pyrimido(4,5-b)indole derivatives: crf1 specific ligands
GB9911863D0 (en) 1999-05-21 1999-07-21 Knoll Ag Therapeutic agents
AU773505B2 (en) 1999-06-18 2004-05-27 Merck & Co., Inc. Arylthiazolidinedione and aryloxazolidinedione derivatives
GB9914977D0 (en) 1999-06-25 1999-08-25 Glaxo Group Ltd Chemical compounds
JP2003504082A (ja) 1999-07-09 2003-02-04 コヘージョン テクノロジーズ， インコーポレイテッド エカリンポリペプチド、エカリンをコードするポリヌクレオチド、及びその利用のための方法
ATE245636T1 (de) 1999-07-29 2003-08-15 Lilly Co Eli Benzofurylpiperazine: 5-ht2c serotoninrezeptor agonisten
KR20020033778A (ko) 1999-09-01 2002-05-07 로버트 흐라이탁, 미쉘 베스트 설포닐 카복스아미드 유도체, 이의 제조방법 및약제로서의 이의 용도
TWI302149B (en) 1999-09-22 2008-10-21 Bristol Myers Squibb Co Substituted acid derivatives useful as antiodiabetic and antiobesity agents and method
PT1237855E (pt) 1999-12-03 2004-06-30 Astrazeneca Ab Forma cristalina do acido (s)-2-etoxi-3-¬4-(2-{4-metanosulfoniloxifenil}etoxi)fenil|propanoico
SE9904413D0 (sv) 1999-12-03 1999-12-03 Astra Ab Comminuted form
CA2400226C (fr) 2000-03-31 2007-01-02 Probiodrug Ag Procede destine a ameliorer le signalement d'ilots dans le diabete sucre et a prevenir ce dernier
YU80302A (sh) 2000-04-25 2005-11-28 Kyorin Pharmaceutical Co. Ltd. Novi stabilni kristal derivata tiazolidinediona i postupak za proizvodnju istog
PT1277736E (pt) 2000-04-28 2007-10-12 Asahi Kasei Pharma Corp Novos compostos bicíclicos
ES2252230T3 (es) 2000-05-11 2006-05-16 Bristol-Myers Squibb Company Analogos de tetrahidroisoquinolina utiles como secretores de la hormona del crecimiento.
AU2001264977B2 (en) 2000-05-30 2005-04-14 Merck & Co., Inc. Melanocortin receptor agonists
TR200401029T4 (tr) 2000-06-09 2004-06-21 Aventis Pharma Deutschland Gmbh Asilfenil-üre türevleri, imalat yöntemleri ve ilaç maddesi olarak kullanımları
TWI243162B (en) 2000-11-10 2005-11-11 Taisho Pharmaceutical Co Ltd Cyanopyrrolidine derivatives
KR100833089B1 (ko) 2000-12-21 2008-05-29 사노피-아벤티스 도이칠란트 게엠베하 신규한 1,2-디페닐아제티딘온 및 당해 화합물을 함유하는 지질 대사 장애를 치료하기 위한 약제학적 조성물
EP1368011A1 (fr) 2001-02-22 2003-12-10 SmithKline Beecham Corporation Methode de traitement de maladies ou de conditions induites par ppar gamma
DE10112768A1 (de) 2001-03-16 2002-09-19 Merck Patent Gmbh Phenylderivate 3
GB0111523D0 (en) 2001-05-11 2001-07-04 Glaxo Group Ltd Chemical compounds
PE20021091A1 (es) 2001-05-25 2003-02-04 Aventis Pharma Gmbh Derivados de fenilurea sustituidos con carbonamida y procedimiento para su preparacion
DE10154689A1 (de) 2001-11-09 2003-05-22 Probiodrug Ag Substituierte Aminoketonverbindungen
PT1425014E (pt) 2001-08-31 2007-03-30 Sanofi Aventis Deutschland Derivados diarilcicloalquilo, processo para a sua preparação como activadores de ppar
AU2002347985A1 (en) * 2001-11-15 2003-06-10 Eli Lilly And Company Peroxisome proliferator activated receptor alpha agonists
DE10215908B4 (de) 2002-04-11 2005-08-18 Aventis Pharma Deutschland Gmbh Acyl-3-carboxyphenyl-harnstoffderivate und deren Verwendung als Arzneimittel
DE10215907A1 (de) 2002-04-11 2003-11-06 Aventis Pharma Gmbh Acyl-4-carboxyphenyl-harnstoffderivate, Verfahren zu deren Herstellung und deren Verwendung
DE10225635C1 (de) 2002-06-07 2003-12-24 Aventis Pharma Gmbh N-Benzoylureido-Zimtsäurederivate, Verfahren zu deren Herstellung und deren Verwendung
EP1615900A1 (fr) 2003-04-01 2006-01-18 Eli Lilly And Company Amides de l'acide benzisothiazol-3-one-carboxylique inhibiteurs des phospholipase
EP1613608A1 (fr) 2003-04-01 2006-01-11 Eli Lilly And Company Inhibiteurs de la phospholipase
DE102004005172A1 (de) 2004-02-02 2005-08-18 Aventis Pharma Deutschland Gmbh Indazolderivate als Inhibitoren der Hormon Sensitiven Lipase
CN101273036A (zh) * 2005-09-29 2008-09-24 塞诺菲-安万特股份有限公司 具有苯基的苯基-[1,2,4]-噁二唑-5-酮衍生物、它们的制备方法和它们作为药物的用途

Also Published As

Publication number Publication date
PE20060323A1 (es) 2006-03-31
CN100582104C (zh) 2010-01-20
SV2006002071A (es) 2006-01-30
US20080262052A1 (en) 2008-10-23
DE602005015204D1 (de) 2009-08-13
US7709509B2 (en) 2010-05-04
PA8628701A1 (es) 2006-11-25
CR8572A (es) 2007-12-04
TW200602342A (en) 2006-01-16
HK1100408A1 (zh) 2007-09-21
AU2005231916A1 (en) 2005-10-20
PL1740583T3 (pl) 2009-12-31
US20070179191A1 (en) 2007-08-02
EP1586573B1 (fr) 2007-02-07
ES2329484T3 (es) 2009-11-26
KR20060135857A (ko) 2006-12-29
EP1740583B1 (fr) 2009-07-01
PT1740583E (pt) 2009-09-16
DK1740583T3 (da) 2009-10-19
EP2083006A1 (fr) 2009-07-29
AR050576A1 (es) 2006-11-08
RU2006138498A (ru) 2008-05-10
MY142431A (en) 2010-11-30
CY1109370T1 (el) 2014-07-02
CA2561627A1 (fr) 2005-10-20
IL178056A0 (en) 2006-12-31
EP1586573A1 (fr) 2005-10-19
WO2005097786A1 (fr) 2005-10-20
RU2374243C2 (ru) 2009-11-27
UY28837A1 (es) 2005-10-31
EP1740583A1 (fr) 2007-01-10
HRP20090493T1 (hr) 2009-10-31
TNSN06317A1 (en) 2007-12-03
ZA200606870B (en) 2008-04-30
BRPI0509517A (pt) 2007-09-11
NO20064981L (no) 2006-12-28
CN1938300A (zh) 2007-03-28
RS51186B (sr) 2010-10-31
ATE435225T1 (de) 2009-07-15
UA84203C2 (en) 2008-09-25
GT200500028A (es) 2006-06-09
ECSP066892A (es) 2006-11-24
US20080255212A1 (en) 2008-10-16
SI1740583T1 (sl) 2009-12-31
JP2007530612A (ja) 2007-11-01
DOP2005000051A (es) 2005-12-15
DE602004004631D1 (de) 2007-03-22

Similar Documents

Publication Publication Date Title
FR18C1024I2 (fr) Derives d'heterocyclocarboxamide
EP1973405A4 (fr) Derives d'hydroxyalkymarylamide
FR15C0062I1 (fr) Nouveaux derives d'oxazolidinone
DK1664036T3 (da) Benzimidazolonforbindelser med 5-HT4-receptoragonistisk virkning
ATE499347T1 (de) Amidderivate
EP1587535A4 (fr) Derives de n-cyclohexylaminocarbonyl benzenesulfonamide
ATE451364T1 (de) Als modulatoren des dopamin-d3-rezeptors geeignete azabicycloä3.1.0ühexanderivate
ATE352550T1 (de) Chinazolinderivate
MA28495B1 (fr) Derives d'oxadiazolone agonistes de ppar-delta
EP1717225A4 (fr) Derives d'amides bicycliques
ATE432282T1 (de) 2-alkinyl- und 2-alkenyl-pyrazolo-ä4,3-eü -1,2,4- triazolo-ä1,5-cü -pyrimidinadenosin a2a rezeptorantagonisten
DK1652843T3 (da) Amidderivater
NO20054669D0 (no) Substituerte kinobenzoxazinanaloger
MA28686B1 (fr) Derives de pyrrolopyridine
FI20045126L (fi) Houkutin kalastusta varten
EP1701948A4 (fr) Essai d'entactogenes
ATE354365T1 (de) N-thiazol-2-yl-benzamid-derivate
ITPN20050014A1 (it) "piedino livellatore perfezionato"
DE602004007387D1 (de) 5-substituierte chinazolinonderivate
DE60324018D1 (de) Agonisten
FR2878850B1 (fr) Derives de l'inositol-1-phosphate
DK1874761T3 (da) 4h-1,2,4-triazin-5-on-derivater, fremstilling heraf og anvendelse heraf som alpha-7-nikotin-acetylcholin-receptorer
EP1658301A4 (fr) Composes n-desmethyl-11-desoxyerythromycine-n-substitues
FI20030668L (fi) Pienten osien syöttölaite
FR2887259B1 (fr) CONSTRUCTION D'ADNc D'ALPHAVIRUS DE SALMONIDES